108 related articles for article (PubMed ID: 18458567)
1. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.
Shimasaki N; Mori T; Torii C; Sato R; Shimada H; Tanigawara Y; Kosaki K; Takahashi T
J Pediatr Hematol Oncol; 2008 May; 30(5):347-52. PubMed ID: 18458567
[TBL] [Abstract][Full Text] [Related]
2. The effects of genetic polymorphism on toxicity and pharmacokinetics of methotrexate in Egyptian adult patients with leukaemia or lymphoma.
Shendy K; Abdelkawy K; Ali AA; Belal F; Abdelhakiem M; Magdy G; Anber N; Elbarbry F
Xenobiotica; 2024 Feb; 54(2):95-105. PubMed ID: 38381003
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapeutic metabolism presenting as a recalcitrant case of hand-foot syndrome and mucositis.
Kwan KR; Skokan S; Blesh-Boren T; Vogel J; Harter N; Ford JB
J Oncol Pharm Pract; 2024 Apr; 30(3):584-588. PubMed ID: 38204187
[TBL] [Abstract][Full Text] [Related]
4. [Association between mthfr gene polymorphisms and toxicity of HDMTX chemotherapy in acute lymphocytic leukemia].
Liu JX; Chen JP; Tan W; Lin DX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):488-92. PubMed ID: 18549614
[TBL] [Abstract][Full Text] [Related]
5. Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL.
Dorababu P; Naushad SM; Linga VG; Gundeti S; Nagesh N; Kutala VK; Reddanna P; Digumarti R
Pharmacogenomics; 2012 Jul; 13(9):1001-8. PubMed ID: 22838948
[TBL] [Abstract][Full Text] [Related]
6. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
[TBL] [Abstract][Full Text] [Related]
8. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue.
Chiusolo P; Giammarco S; Bellesi S; Metafuni E; Piccirillo N; De Ritis D; Marietti S; Federica S; Laurenti L; Fianchi L; Hohaus S; Giuseppe L; Sica S
Cancer Chemother Pharmacol; 2012 Mar; 69(3):691-6. PubMed ID: 21984221
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
[TBL] [Abstract][Full Text] [Related]
10. Association of
Razali RH; Noorizhab MNF; Jamari H; James RJ; Teh KH; Ibrahim HM; Teh LK; Salleh MZ
Pediatr Hematol Oncol; 2020 Apr; 37(3):185-197. PubMed ID: 31870219
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia.
Esmaili MA; Kazemi A; Faranoush M; Mellstedt H; Zaker F; Safa M; Mehrvar N; Rezvany MR
Iran J Basic Med Sci; 2020 Jun; 23(6):800-809. PubMed ID: 32695297
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate.
Cwiklinska M; Czogala M; Kwiecinska K; Madetko-Talowska A; Szafarz M; Pawinska K; Wieczorek A; Klekawka T; Rej M; Stepien K; Halubiec P; Lazarczyk A; Miklusiak K; Bik-Multanowski M; Balwierz W; Skoczen S
Front Pediatr; 2020; 8():307. PubMed ID: 32612964
[No Abstract] [Full Text] [Related]
13. Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia.
Yousef AM; Farhad R; Alshamaseen D; Alsheikh A; Zawiah M; Kadi T
Cancer Chemother Pharmacol; 2019 Apr; 83(4):755-762. PubMed ID: 30684021
[TBL] [Abstract][Full Text] [Related]
14. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
15. Associations between gene polymorphisms and treatment outcomes of methotrexate in patients with juvenile idiopathic arthritis.
Chen Y; Zou K; Sun J; Yang Y; Liu G
Pharmacogenomics; 2018 Apr; 19(6):529-538. PubMed ID: 29589488
[TBL] [Abstract][Full Text] [Related]
16. Associations between the C677T and A1298C polymorphisms of MTHFR and the toxicity of methotrexate in childhood malignancies: a meta-analysis.
Zhu C; Liu YW; Wang SZ; Li XL; Nie XL; Yu XT; Zhao LB; Wang XL
Pharmacogenomics J; 2018 May; 18(3):450-459. PubMed ID: 28696419
[TBL] [Abstract][Full Text] [Related]
17. Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis.
Chen Y; Zou K; Sun J; Yang Y; Liu G
Pharmacogenomics; 2017 Jan; 18(2):175-195. PubMed ID: 27992285
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate elimination and toxicity: MTHFR 677C>T polymorphism in patients with primary CNS lymphoma treated with high-dose methotrexate.
Choi YJ; Park H; Lee JS; Lee JY; Kim S; Kim TW; Park JS; Kim JE; Yoon DH; Suh C
Hematol Oncol; 2017 Dec; 35(4):504-509. PubMed ID: 27781293
[TBL] [Abstract][Full Text] [Related]
19. Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies.
Tsujimoto S; Yanagimachi M; Tanoshima R; Urayama KY; Tanaka F; Aida N; Goto H; Ito S
Pediatr Blood Cancer; 2016 Nov; 63(11):1983-9. PubMed ID: 27399166
[TBL] [Abstract][Full Text] [Related]
20. Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis.
Jenko B; Lusa L; Tomsic M; Praprotnik S; Dolzan V
Pharmacogenomics J; 2017 Oct; 17(5):412-418. PubMed ID: 27217051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
